The Korean Journal of Blood Transfusion : eISSN 2383-6881 / pISSN 1226-9336

Table. 1.

Table. 1.

Interpretations and approaches to panagglutination reaction on antibody identification test

PanagglutinationAutocontrolInterpretationApproach
PositivePositive1. Autoantibody1. Autologous adsorption (e.g., PEG, ZZAP, etc.)
2. Alloantibodies with autoantibody2. Autologous adsorption (e.g., PEG, ZZAP, etc.)/ Enzyme modification (e.g., ficin, papain, etc.)/ Chemical modification (e.g., DTT, AET, 2-ME, etc.)
3. Therapeutic monoclonal antibody-induced interference (e.g., anti-CD47, daratumumab, etc.)3. History taking of drugs including daratumumab, anti- CD47. If yes, then test with DTT-treated RBCs and/or multiple RBC alloadsorptions [3]. (Recommend extended RBC phenotyping before drug administration)
Negative1. Antibodies to high-incidence antigens1. Test with antigen-negative RBCs/ Phenotyping with antisera containing suspicious alloantibody
2. Multiple alloantibodies (Agglutination strength may be variable.)2. Enzyme modification (e.g., ficin, papain, etc.)/ Chemical modification (e.g., DTT, AET, 2-ME, etc.)/ Temperature reduction (room temperature or below)
3. Therapeutic monoclonal antibody-induced interference (e.g., daratumumab, anti-CD47, etc.)3. History taking of drugs including daratumumab, CD-47. If yes, then test with DTT-treated RBCs and/or multiple RBC alloadsorptions [3]. (Recommend extended RBC phenotyping before drug administration)

Abbreviations: 2-ME, 2-mercaptoethanol; AET, 2-aminoethylisothiouronium bromide; DTT, dithiothreitol; PEG, polyethylene glycol; RBC, red blood cell.

Korean J Blood Transfus 2019;30:101-12 https://doi.org/10.17945/kjbt.2019.30.2.101
© 2019 Korean J Blood Transfus